Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian court supports Excedrin headache superiority claims over Tylenol.

This article was originally published in The Tan Sheet

Executive Summary

EXCEDRIN HEADACHE SUPERIORITY AD CLAIMS OVER TYLENOL are supported in a recent decision by the Ontario Court of Justice in Toronto. On July 25, Judge Donald Taliano denied a McNeil Consumer Products motion for an interlocutory injunction restraining Bristol-Myers Squibb from making statements and distributing ads that claim Excedrin is superior to Tylenol for headache or other pain relief because it contains caffeine.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel